-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Ascentage Pharma Secures FDA IND Clearance For BTK Degrader APG-3288 Advancing Global Phase I Development In B Cell Malignancies

Benzinga·01/07/2026 06:41:58
Listen to the news
  • Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company's global innovative pipeline.
  • Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies.